![](https://d3ilqtpdwi981i.cloudfront.net/cZg2MnpunK71uP-kOdiSGde5qEI=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/e3/4c/1a/e34c1a73-6f0a-4adc-b90a-74dabd4b3cfd/thumbnail_0ac57db3-525f-4500-9828-4da0b008e8c4.jpg)
Conclusions: In the Aurora cohort of patients with "transient" LV dysfunction recovered to EF≥40%, characteristics of ICD recipients were similar to prior primary prevention ICD trials. ICD recipients were more likely to have diabetes, and EF improved to a lesser degree and over a longer period. An associated between presence of ICD and better all-cause survival was observed. This difference was driven by a benefit in patients with EF 40-49%.
Our findings suggest: in patients who develop significant LV dysfunction, recovery of LV function to EF>35% does not afford adequate SCD protection, and that ICD therapy may be appropriate and protective in patients with EF improved up to 49%.
Singh K, Zahwe F, Omery B, Ballany W, Shearer R, Mengesha T, Choudhuri I. Benefit of implantable cardioverter-defibrillator in patients with improved left ventricular systolic function. Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.
Aurora Cardiovascular Services, Department of Electrophysiology, Department of Cardiology, Cardiovascular Data Services, Aurora Health Care, Aurora Research Institute